Horizon Technology Finance Corp 8-K

What Happened

• Horizon Technology Finance (HRZN) disclosed that it and Monroe Capital Corporation (MRCC) entered a Merger Agreement (effective Aug 7, 2025) providing for a two-step merger after MRCC sells its investment assets to Monroe Capital Income Plus (MCIP).
• On Jan 30, 2026 HRZN was named in a putative class action in Delaware (and two similar complaints in New York) alleging the joint proxy statement filed Jan 20, 2026 contains materially misleading or incomplete disclosures. HRZN denies the allegations but voluntarily supplemented the joint proxy statement to reduce litigation risk.
• The HRZN Board — on the recommendation of a special committee of independent directors — unanimously recommends HRZN shareholders vote “FOR” the merger stock issuance proposal and the director election proposal. A special meeting of HRZN shareholders is set for March 13, 2026 at 2:30 p.m. ET.

Key Details

• Litigation: Putative class action filed Jan 30, 2026 in Delaware; two additional complaints filed in New York (collectively, the “Merger Complaints”). HRZN says claims are without merit but chose to supplement disclosures.
• Supplemental disclosures clarify that certain forecasted financial information (unaudited, prepared for internal use) was provided by MC Advisors and HRZN Advisor based on information as of June 30, 2025 and is not GAAP, not audited, and not intended to be predictive.
• Selected projections included in the supplement (standalone and pro forma):
  • MRCC standalone (2026–2030) estimated net investment income/share: $0.31, $0.26, $0.28, $0.29, $0.31; estimated dividends/share: $0.28, $0.24, $0.25, $0.26, $0.28; NAV/share (12/31 each year): $8.06 → $8.14.
  • HRZN standalone (2026–2030) estimated net investment income/share: $1.05, $1.02, $1.03, $1.05, $1.06; estimated dividends/share: $1.00 annually; NAV/share: $6.60 → $6.87.
  • Combined pro forma (2026–2030) estimated net investment income/share: $1.05, $1.02, $1.11, $1.17, $1.24; dividends/share: $1.00 annually; NAV/share: $6.55 → $7.89.
• The disclosure also expands on potential conflicts and prior/possible future engagements of HRZN’s financial advisor Oppenheimer. The supplement states these projections do not change the merger consideration or the timing of the March 13, 2026 special meeting.

Why It Matters

• For investors, the filing signals a live legal risk that could delay or increase the cost of closing the proposed transactions, although HRZN is proceeding with supplemental disclosures and urging shareholders to vote.
• The included forecasts provide management and advisors’ expectations for standalone and combined results through 2030, but the company explicitly warns the forecasts are unaudited, not GAAP, based on assumptions as of June 30, 2025, and may not predict actual results.
• The HRZN Board’s unanimous recommendation to vote for the merger is material to shareholder action at the March 13, 2026 meeting; investors should read the updated joint proxy/registration statement and monitor any litigation developments or regulatory approvals.